Table of Contents
Research & Development
| Gene Therapy Start-Up Voyager Therapeutics Impresses with US$845 M Genzyme Deal | Abstract |
| Heather Cartwright |
Mergers & Acquisitions
| Valeant Settles for Second Best with US$14.5 B Salix Acquisition | Abstract |
| Heather Cartwright |
| BMS Bets US$800 M Upfront That Flexus’ Preclinical IDO1 Inhibitor Is Best-in-Class | Abstract |
| Heather Cartwright |
| AbbVie Gambles US$21 B that Pharmacyclics’ Imbruvica® will Achieve Upside Potential | Abstract |
| Heather Cartwright |
Opinion & Analysis
| IMS PharmaDeals Review of 2014 | Abstract |
| Heather Cartwright & Taskin Ahmed |
This work is licensed under a Creative Commons Attribution 3.0 License.